In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series D brings in an initial $25mm for Intact Vascular

Executive Summary

Intact Vascular Inc. (minimally invasive devices for peripheral vascular procedures) raised $25mm through its Series D financing led by Vensana Capital, which was joined by returning shareholders New Enterprise Associates, HIG BioHealth Partners, and Quaker Partners. The company expects another tranche in 2020. Intact Vascular will use the funds to expand sales and marketing activities, and clinical support staffing for its Tack endovascular system for dissection repair following above-the-knee balloon angioplasty. Concurrently, Vesper Medical Inc., which spun out from Intact Vascular in 2016 and is also developing devices for minimally invasive peripheral vascular procedures, raised $37mm in a financing from Vensana Capital, Gilde Healthcare, NEA, and Quaker Partners.

Deal Industry
  • Medical Devices
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies